D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile
Sophie Valleix(Délégation Paris 5), Vittorio Bellotti(University of Pavia), Noémie Jourde‐Chiche(Aix-Marseille Université), Marc Delpech(Université Paris Cité), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Gilles Grateau(Sorbonne Université), Philip N. Hawkins(The Royal Free Hospital), Oleg Kovrov(Umeå University), Marie Lhomme(Sorbonne Université), Riccardo Porcari(University of Pavia), Monica Stoppini(University of Pavia), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Anatol Kontush(Inserm), Christopher A. Waudby(University College London), Carolane Dauteuille(Sorbonne Université), P. Patrizia Mangione(University of Pavia), John Christodoulou(The University of Sydney), Guglielmo Verona(University of Pavia), Annalisa Relini(University of Genoa), Brigitte Nédelec(Institut Cochin), Frank Bridoux(Université de Poitiers), Alain Mangé(Inserm), Jean-Michel Goujon(Université de Poitiers), Athina Kalopissis(Délégation Paris 5), Philippa J. Talmud(University College London), Michèle Chabert(Délégation Paris 5), Gunilla Olivecrona(Lipigon Pharmaceuticals (Sweden))
Cited by 66
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k